GlassScriptPhysician profile
James Underwood
NPI 1447240494
$1,570.12
in general payments reported to CMS, 2019-2025
19 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $142 · 2021: $178 · 2022: $361 · 2023: $79.61 · 2024: $128 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621.44 | 2019-2025 | Creon, Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $184.67 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.83 | 2019-2024 | Trulance |
| Fujifilm Healthcare Americas Corporation | $153.55 | 2022 | |
| Janssen Scientific Affairs, LLC | $92.62 | 2019 | |
| Pfizer INC. | $70.42 | 2019 | |
| Celgene Corporation | $50.91 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $33.40 | 2022-2025 | |
| Janssen Biotech, INC. | $29.84 | 2019-2020 | |
| Madrigal Pharmaceuticals | $29.59 | 2025 | Rezdiffra |
| Ardelyx, INC. | $22.15 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $20.58 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $20.01 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Merck Sharp & Dohme LLC | $16.24 | 2024 | Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $15.28 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $13.62 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $12.85 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,139.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Underwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.